SEC Form 4 · accession 0001179110-15-011301
MERRIMACK PHARMACEUTICALS INC · MACK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William A. Sullivan
Officer — CFO and Treasurer
Period of report
Jul 15, 2015
Accepted (ET)
Jul 17, 2015 · 4:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001274792
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 15, 2015 | M | 10,596 | $2.12 | A | 21,596 | D | |
| Common Stock | Jul 15, 2015 | M | 4,404 | $2.12 | A | 26,000 | D | |
| Common StockF2 | Jul 15, 2015 | S | 15,000 | $11.85 | D | 11,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $2.12 | Jul 15, 2015 | M | 10,596 | D | — | Dec 4, 2017 | Common Stock | 10,596 | 0 | D |
| Stock Option (right to buy)F3 | $2.12 | Jul 15, 2015 | M | 4,404 | D | — | May 5, 2018 | Common Stock | 4,404 | 12,096 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.71 to $11.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F3This option is fully vested.